Research advances in associations between IL28B polymorphisms and chronic hepatitis B /C virus infection

Shen WenJuan; Ha MingHao

doi:10.3969/j.issn.1001-5256.2014.10.028

Issue 10

Oct. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(10): 1087-1090

PDF( 1350 KB)

Research advances in associations between IL28B polymorphisms and chronic hepatitis B /C virus infection

DOI: 10.3969/j.issn.1001-5256.2014.10.028

Department of Infectious Diseases, Shanghai Seventh People's Hospital

Research funding:

Received Date: 2014-03-21
Published Date: 2014-10-20

Abstract

Abstract

Chronic infection with hepatitis B/C virus ( HBV/HCV) is a widespread epidemic in China. The single nucleotide polymorphisms ( SNPs) in interleukin 28B ( IL28B) gene have been associated with chronic HBV/HCV infection and response to interferon therapy. The biological functions and characteristics of IL28 B are elaborated on, the associations between HCV infection and IL28 B SNPs are commented on, and current reports of associations between HBV infection and IL28 B SNPs are reviewed. The results support the associations between IL28 B SNPs and disease progression of HCV infection or the curative effect of interferon therapy. However, contradictive results have been obtained in studies of associations between IL28 B SNPs and disease progression of HBV infection, the incidence of liver cirrhosis and primary liver cancer after HBV infection, or the curative effect of interferon therapy, so further investigation is needed.
- hepatitis B,
- hepatitis C,
- interleukins,
- polymorphism, single nucleotide,
- review

FullText(HTML)

References(36)

References

[1]GANEM D, PRINCE AM.Hepatitis B virus infection--naturat history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[2]World Health Organization.Hepatitis B[EB/OL]. (2008-08) [2010-12-09]http//www.who.int/mediacentre/factsheets/fs204/en/.

[3]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaceination[J].Vaccine, 2009, 27 (47) :6550-6557.

[4]LIANG X, BI S, YANG W, et al.Evaluation of the impact of hepatitis B vaccination among children bom during 1992-2005 in China[J].J Infect Dis, 2009, 200 (1) :39-47.

[5] LU FM, ZHUANG H.Management of hepatifis B in China[J].Chin Med J (Engl) , 2009, 122 (1) :3-4.

[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南2010年版[J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[7]YANG M, RAO HY.Key points of the AASLD's guidelines on hepatitis C diagnosis and treatment[J].J Clin Hepatol, 2013, 29 (2) :9-14. (in Chinese) 杨明, 饶慧瑛.美国肝病学会丙型肝炎诊治指南要点[J].临床肝胆病杂志, 2013, 29 (2) :9-14.

[8]KETENKO SV, GALLAGHER G, BAURIN VV, et al.IFN-lambads mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol, 2003, 4 (1) :69-77.

[9]UZG, MONNERON D.IL-28 and IL-29:newcomers to the interferon family[J].Biochimie, 2007, 89 (6-7) :729-734.

[10]ANK N, WEST H, PALUDAN SR.IFN-lambda:novel antiviral cytokine[J].J Interferon Cytokine Res, 2006, 26 (6) :373-379.

[11]O'BRIEN TR.Interferon-alfa, Interferon-lambda and hepatitis C[J].Nat Genet, 2009, 41 (10) :1048-1050.

[12]IADONATO SP, KAEZE MG.Genomics:Hepatitis C virus gets personal[J].Nature, 2009, 461 (7262) :357-358.

[13]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[14]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment—induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[15]RAUCH A, KUTALILC Z, DESCOMBES P, et al.Genetic Variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide associationstudy[J].Gastroentemlogy, 2010, 138 (4) :1338-1345.

[16]MANGIA A, THOMPSON A, SANTORO R, et al.An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3patients who do not achieve a rapid virologic response[J].Gastroenterology, 2010, 139 (3) :821-827.

[17]MCCARTHY JJ, LI JH, THOMPSON A, et al.Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin[J].Gastroenterology, 2010, 138 (7) :2307-2314.

[18]REMBECK K, ALSIA, CHRISTENSEN PB, et al.Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3[J].PLoS One, 2012, 7 (1) :e29370.

[19]JACOBSON IM, MCHUTCHISON JG, DUSHEIKO G, et al.Telaprevir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med, 2011, 364 (25) :2405-2416.

[20]HONDA M, SAKAI A, YAMASHITA A, et al.Hepatic ISG exprsssion is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C[J].Gastroenterology, 2010, 139 (2) :499-509.

[21]URBAN TJ, THOMPSON AJ, BRADRICK SS, et al.IL28B genotype is associated with differential expression of intrahepatic interferon, stimulated genes in patients with chronic hepatitis C[J].Hepatology, 2010, 52 (6) :1888-1896.

[22]SAITO H, ITO K, SUGIYAMA M, et al.Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients[J].Hepatol Res, 2012, 42 (10) :958-965.

[23]BOCHUD PY, BIBERT S, KUTALIK Z, et al.IL28B alleles associated with poor Hepatitis C clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes[J].Hepatology, 2012, 55 (2) :384-394.

[24]MARABITA F, AGHEMO A, DE NICOLA S, et al.Genetic variation in the interleukin-28B gene is not associated with fibrosisi progression in patients with chronic hepatitis C and known date of infection[J].Hepatology, 2011, 54 (4) :1127-1134.

[25]AL-QAHTANI AA, AL-ANAZI MR, ABDO AA, et al.Genetic variation in interleukin 28 B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients[J].Liver Int, 2014, 34 (7) :e208-e216.

[26]CHENG L, SUN X, TAN S, et al.Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients[J].Hepatol Res, 2014, 44 (9) :1000-1007.

[27]ZHANG Q, LAPALUS M, ASSELAH T, et al.IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients[J].J Virol Hepat, 2014, 21 (7) :525-532.

[28]CHEN J, WANG L, LI Y, et al.Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese[J].PLoS One, 2012, 7 (12) :e50787.

[29]LEE IC, LIN CH, HUANG YH, et al.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B[J].PLoS One, 2013, 8 (2) :e58071.

[30]TAMORI A, KAWADA N.HLA classⅡassociated with outcomes of hepatitis B and C infections[J].World J Gastroenterol, 2013, 19 (33) :5395-5401.

[31]KIM SU, SONG KJ, CHANG HY, et al.Association between IL28B Polymorphisms and spontaneous clearance of hepatitis B virus infection[J].PLoS One, 2013, 8 (7) :e69166.

[32]GARCIA-SAMANIEGO J, ROMERO M, GRANADOS R, et al.Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C[J].World J Gastroenterol, 2013, 19 (12) :1943-1952.

[33]LI W, JIANG Y, JIN Q, et al.Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population[J].Liver Int, 2011, 31 (8) :1118-1126.

[34]MARTIN MP, QI Y, GOEDERT JJ, et al.IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection[J].J Infect Dis, 2012, 202 (11) :1749-1753.

[35]LAMPERTICO P, VIGANOM, CHERONI C, et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology, 2013, 57 (3) :890-896.

[36]SONNEVELD MJ, WONG VW, WOLTMAN AM, et al.Polymorphisms near IL28B and serologic response to peginterferon in HbeAg positive patients with chronic hepatitis B[J].Gastroenterology, 2012, 142 (2) :513-520.

Relative Articles

[1]	Chuanfu QIN, Yali ZHAO, Lijuan LONG, Hua QIU. Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation[J]. Journal of Clinical Hepatology, 2023, 39(10): 2340-2347. doi: 10.3969/j.issn.1001-5256.2023.10.011
[2]	Tianyu LI, Huimin YAN. Mechanism of action of forkhead box transcription factors in hepatocellular carcinoma and their prospects as treatment targets[J]. Journal of Clinical Hepatology, 2021, 37(4): 931-934. doi: 10.3969/j.issn.1001-5256.2021.04.044
[3]	Xiaoke RAN, Xinju CHEN, Yunxia ZHAO, Xin ZHANG, He YANG, Yiyao SUN, Xiaoqi CHEN. Expression and clinical significance of forkhead box A2 and forkhead box J2 in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(6): 1342-1347. doi: 10.3969/j.issn.1001-5256.2021.06.025
[4]	Wang ShanShan, Zhang QingShan, Zhao SuXian, Kong LingBo, Ji Lei, Kong Li. The immunoregulatory effect of tumor necrosis factor-alpha-induced protein 8-like 2 in different liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 460-463. doi: 10.3969/j.issn.1001-5256.2020.02.050
[5]	Li Tian, Wu Yan, Ji Ting, Jin ZhenXiao. Role of FOXO1/3 in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1842-1846. doi: 10.3969/j.issn.1001-5256.2019.08.043
[6]	Kong Li, Zhang YuZhuo, Jin Meng, Wang ShanShan, Du JingHua, Zhang YuGuo, Wang RongQi, Ren WeiGuang, Nan YueMin. mRNA expression and significance of tumor necrosis factor-alpha-induced protein 8-like 2 and forkhead box P3 in peripheral blood mononuclear cells in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2019, 35(12): 2721-2724. doi: 10.3969/j.issn.1001-5256.2019.12.016
[7]	Li Yu, Zhang Hong, Li Zhu, Liu QingE, Wang Lu, Zhang Dan, Cao NingJia, Su Li. Influence of the Notch signaling pathway on CD8⁺T lymphocyte function in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 287-291. doi: 10.3969/j.issn.1001-5256.2018.02.014
[8]	Guo FeiBo, Wu JunZhu, Ai LiMing, Song Ying. Clinical significance of Th17/Treg and associated cytokines in peripheral blood in chronic hepatitis C patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 479-484. doi: 10.3969/j.issn.1001-5256.2017.03.017
[9]	Kong Li, Jin Meng, Zhao SuXian. Role of tumor necrosis factor- alpha- induced protein 8-like 2 in development and progression of liver and gastrointestinal tumors[J]. Journal of Clinical Hepatology, 2017, 33(1): 175-179. doi: 10.3969/j.issn.1001-5256.2017.01.041
[10]	Guo FeiBo. Change in peripheral blood CD4~+ regulatory T cells and its association with antiviral effect in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(12): 2317-2321. doi: 10.3969/j.issn.1001-5256.2016.12.017
[11]	Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
[12]	Chen RuiLin, Lin ShuMei, Zhang ShuLin, Ye Feng, Zhang Xi, Zhao YingRen. Detection of the replicative state of HBV in peripheral blood mononuclear cells by improving PCR[J]. Journal of Clinical Hepatology, 2008, 24(5): 328-331.
[14]	Cui Fang, Wang DongPing. Detection of HBV DNA in periphereal blood mononuclear cells of patients with hepatitis B by FQ-FCR and its significance[J]. Journal of Clinical Hepatology, 2006, 22(2): 97-98.
[16]	Zhang Biao, Sui Tao, Yu XiuYing, Cao YongXian, Yao Yuan, He Hong. Significance of detecting apoptosis of PBMC and cytokine of supernatant induced by PHA in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(3): 138-140.
[17]	Song MinNing, Luo MeiLan, Huang WenQi, Min Feng. The study of levels of IL-10, IL-12 and γ-IFN in the culture medium of peripheral blood mononuclear cells from HBeAg positive chronic asymptomatic HBV patient[J]. Journal of Clinical Hepatology, 2003, 19(3): 176-177.
[19]	Zhang KaiYu, Cai YanJun, Wang Feng, Xu Chang, Lu: MeiDe. Study on Relationship between Detection of Hepatitis B Virus Replicative Intermediates RNA and Hepatitis B Virus DNA in Peripheral Blood Mononuclear Cells in Patients with Hepatitis B Virus Infection[J]. Journal of Clinical Hepatology, 2001, 17(3): 149-151.
[20]	Zhang KaiYu, Wang Feng, Lou JinFeng, Cai YanJun, Lu: MeiDe. Detection of Hepatitis B virus Replicative Intermediates RNA in Peripheral Blood Mononuclear cells in patients with Hepatitis B virus Infection and its clinical significance[J]. Journal of Clinical Hepatology, 2000, 16(2): 88-90.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	王德志，胡海洋，郭长华，宋磊. 钆贝葡胺核磁共振增强与CT多期增强扫描对肝硬化伴小肝癌诊断的对比研究. 中西医结合肝病杂志. 2021(05): 449-451 .
2.	赵锦洪，彭德新，杨智利，徐仁根，刘岚，龚良庚. 普美显和马根维显MRI增强对肝硬化背景下小肝癌诊断的对比研究. 江西医药. 2021(07): 915-918 .
3.	罗竹人，汪艳，蔡琳婷，郭春英. 钆塞酸二钠增强MRI与增强CT对肝脏局灶性病变的诊断价值. 中国卫生标准管理. 2020(24): 66-70 .
4.	李艳丽，解玥，汤奉琼，马婷，赵惠菊. 肝脏特异性造影剂(钆塞酸二钠)的应用体会. 智慧健康. 2020(33): 85-86 .
5.	沈丽荣，张立云，戴灼南. 肝胆期钆塞酸二钠磁共振动态增强扫描在肝硬化结节与小肝癌的鉴别诊断中的应用价值. 广州医科大学学报. 2019(02): 44-47 .
6.	陈翔，王苇. 普美显动态增强联合DWI对强化特征不典型肝癌和肝内复发灶的诊断价值. 临床医学研究与实践. 2018(21): 150-151 .
7.	董丽伟，王飞，罗是是，赵应满，陈峰，李建军. 3.0T磁共振钆塞酸二钠增强扫描对肝硬化患者肝脏再生结节良恶性质的鉴别诊断价值. 中国医药导报. 2018(31): 127-130 .
8.	王莉莉，李俊峰，窦郁，郭顺林，雷军强. MR功能成像对肝细胞癌微血管侵犯的评估价值. 临床肝胆病杂志. 2018(12): 2681-2684 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2664) PDF downloads(574)

Research advances in associations between IL28B polymorphisms and chronic hepatitis B /C virus infection

DOI: 10.3969/j.issn.1001-5256.2014.10.028